Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
16/04/2026 18:27
April 16 (Reuters) - AB Science SA ABS.PA: AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL DEVELOPMENT PROGRAM. AB SCIENCE SA: SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS AB SCIENCE SA - IMPLEMENTS VOLUNTARY TEMPORARY HALT OF CLINICAL TRIALS IN EUROPE, BEFORE THE IMPLEMENTATION OF A STRATEGIC REORGANIZATION AB SCIENCE SA - DEPRIORITIZES DEVELOPMENT IN MASTOCYTOSIS AND MAST CELL ACTIVATION PROGRAM AB SCIENCE SA - TO PURSUE PHASE 3 DEVELOPMENT IN MULTIPLE SCLEROSIS AND ALZHEIMER'S THROUGH PARTNERSHIPS AB SCIENCE SA - PRIORITIZES MASITINIB PHASE 3 IN ALS AND AB8939 PHASE 1 IN AML Source text: ID:nGNX4PpsfC Further company coverage: ABS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease